A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer Research (UK) and entered clinical trials in 1991; phase II studies began in 1992, using 3.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, I., Jones, A., Spielmann, M., Namer, M., Green, M. D., Bonneterre, J., Wander, H. E., Hatschek, T., Wilking, N., Zalcberg, J., Spiers, J., Seymour, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074654/
https://www.ncbi.nlm.nih.gov/pubmed/8695369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074654/
https://www.ncbi.nlm.nih.gov/pubmed/8695369

Ejemplares similares